Sep 10, 2026 08:21AM
Sep 10, 2026 08:00AM
Aug 24, 2026 08:01AM
Aug 24, 2026 08:00AM
Aug 11, 2026 04:01PM
Aug 10, 2026 08:02AM
Aug 10, 2026 08:00AM Erasca Strengthens R&D Leadership with Appointment of Internationally Recognized Medical Oncologist Charles S. Fuchs, M.D., M.P.H., as President of R&D
Jul 13, 2026 04:01PM
Jul 13, 2026 04:01PM
Feb 17, 2026 10:48AM
Jan 12, 2026 08:03AM
Nov 19, 2025 09:45AM
Aug 12, 2025 04:01PM
Jun 2, 2025 08:06AM Erasca, Inc (ERAS) Announces IND Clearance for Potential First-in-Class and Best-in-Class Pan-KRAS Inhibitor ERAS-4001
Jun 2, 2025 08:00AM
May 13, 2025 04:05PM
May 13, 2025 08:04AM
May 13, 2025 08:00AM
Mar 25, 2025 04:31PM
Mar 20, 2025 04:01PM
Nov 12, 2024 04:01PM Erasca Reports Third Quarter 2024 Business Updates and Financial Results
Oct 24, 2024 08:02AM
Oct 24, 2024 08:00AM
Sep 25, 2024 08:00AM
Aug 12, 2024 04:01PM
Jun 18, 2024 08:00AM
May 16, 2024 08:03PM
May 16, 2024 08:02PM Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise
May 8, 2024 04:01PM
Apr 24, 2024 04:05PM
Mar 27, 2024 04:01PM
Feb 14, 2024 08:01AM
Feb 14, 2024 08:00AM
Dec 11, 2023 08:03AM
Dec 11, 2023 08:00AM Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma
Nov 28, 2023 08:00AM
Aug 10, 2023 04:01PM
Jun 22, 2023 04:01PM
Jun 22, 2023 04:01PM
May 25, 2023 05:00PM
May 15, 2023 04:01PM
May 1, 2023 08:03AM Erasca, Inc (ERAS) Granted FDA Fast Track Designation for ERAS-801
May 1, 2023 08:00AM
Apr 10, 2023 08:04AM
Apr 10, 2023 08:00AM
Mar 23, 2023 04:01PM
Mar 23, 2023 04:01PM
Dec 13, 2022 08:01AM
Dec 13, 2022 08:00AM Erasca Announces FDA Clearance of IND Application for CNS-Penetrant KRAS G12C Inhibitor ERAS-3490 in KRAS G12C-Mutated Advanced or Metastatic Solid Tumors
Dec 13, 2022 08:00AM

330,674 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All